Full Text View
Tabular View
No Study Results Posted
Related Studies
A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus.
This study is ongoing, but not recruiting participants.
Study NCT00044135   Information provided by Triangle Pharmaceuticals
First Received: August 20, 2002   Last Updated:   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hepatitis B
Additional conditions recognized in this trial
Hepatitis
More general conditions related to this trial
Digestive System Diseases
DNA Virus Infections
Hepadnaviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Virus Diseases
Interventions listed in this trial
clevudine (drug)
Additional drug interventions recognized in this trial
2'-fluoro-5-methylarabinosyluracil
More general drug interventions related to this trial
Anti-Infective Agents
Antiviral Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Triangle Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services